Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02706977 · ClinicalTrials.gov registry record · Phase 1
The Effect of Dopamine on Diabetic Retinopathy
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02706977: Completed Phase 1 study, sponsored by Emory University.
NCT02706977 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02706977, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the use of electroretinogram (ERG) using a novel handheld system, RETeval, and evaluate contrast sensitivity testing in detecting pre-clinical retinopathy on a tablet device. Investigators also seek to assess if a medication called Sinemet™ CR can improve the electrical functions of the eye in participants with diabetes mellitus. This study will include a total of 45 participants; 30 with diabetes mellitus and 15 age-matched non-diabetic controls. Participants with diabetes mellitus and electroretinogram (ERG) delays will be randomized to a low or high dose Sinemet CR group.
Primary Outcome
The RETeval device consists of a hand-held wand with a pupil tracker. A skin electrode placed below the eye or DTL fiber records the response to flash stimuli. The pupil tracker provides feedback to the system so that the flash stimuli can compensate for the pupil size and produce the proper illumination to the retina. RETeval is intended to generate photopic signals and measure and display the electrical response signals generated by the retina and the visual nervous system using flash stimuli.
Interventions
- DRUG Low Dose Sinemet CR
- DRUG High Dose Sinemet CR
- DEVICE RETeval Electroretinogram (ERG) Testing
- OTHER Contrast Sensitivity Testing
- OTHER Visual Acuity Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-08-15 |
| Phase | Phase 1 |
What the finished NCT02706977 record still lists
NCT02706977 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 5 interventions - of which Low Dose Sinemet CR is the first listed.
NCT02706977 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02706977 about?
NCT02706977 is a clinical study titled "The Effect of Dopamine on Diabetic Retinopathy". The purpose of this study is to evaluate the use of electroretinogram (ERG) using a novel handheld system, RETeval, and evaluate contrast sensitivity testing in detecting pre-clinical retinopathy on a tablet device. Investigators also seek to assess if a medication called Sinemet™ CR can improve th...
What is the current status of trial NCT02706977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-01. Estimated completion is 2019-08-15.
What interventions are being tested in trial NCT02706977?
The interventions under investigation include: Low Dose Sinemet CR (DRUG), High Dose Sinemet CR (DRUG), RETeval Electroretinogram (ERG) Testing (DEVICE), Contrast Sensitivity Testing (OTHER), Visual Acuity Testing (OTHER).
Who is sponsoring clinical trial NCT02706977?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02706977's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia